Xylyx Bio, a pioneer in physiomimetic biomaterials, today announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies.
|
NEW YORK, July 23, 2019 /PRNewswire/ -- Xylyx Bio, a pioneer in physiomimetic biomaterials, today announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies.
As part of continuing efforts to incentivize companies to invest in new technology development in the United States, ARMI brings together a consortium of partners from across industry, government, academia and the non-profit sector to advance manufacturing processes and technologies for cells, tissues and organs. According to ARMI, approximately $80 million from the federal government is combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. "When developing bio-inspired replacement tissues, three-dimensional (3D) biomaterial scaffolds play a critical role in new tissue morphogenesis through interaction with human cells," said Andrea Nye, Chief Executive Officer, Xylyx Bio, adding, "To this end, Xylyx Bio offers a variety of tissue-specific extracellular matrix (ECM) biomaterials that support regenerative medicine products and tissue engineering, including skin, bone, cartilage, and heart, among others." Xylyx Bio's biomimetic 3D TissueSpec® ECM Scaffolds provide tissue-specific structure, architecture, topography and composition required for cell attachment and cell-cell communication in support of cell proliferation and differentiation for tissue regeneration. Xylyx Bio's ECM biomaterials can also be utilized in platforms such as 3D bioprinting, bioreactors and others. "Tissue-specific ECM products present the opportunity to plug into other advanced technologies, similar to the way microchips revolutionized the consumer electronics industry," stated Dr. John O'Neill, Co-founder and Chief Scientific Officer at Xylyx Bio. "By joining ARMI, Xylyx will be ideally positioned to work closely with other members towards integrating extracellular matrix as a bioactive class of biomaterials. We are thrilled to work with the ARMI consortium to offer our expertise in tissue-specific ECM biomaterials to help accelerate the development of next generation products within the field of regenerative medicine." About Xylyx Bio Contact
SOURCE Xylyx Bio, Inc. |
View original content to download multimedia:
